455 related articles for article (PubMed ID: 11465876)
1. Ganciclovir: an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients.
McGavin JK; Goa KL
Drugs; 2001; 61(8):1153-83. PubMed ID: 11465876
[TBL] [Abstract][Full Text] [Related]
2. Ganciclovir. An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients.
Noble S; Faulds D
Drugs; 1998 Jul; 56(1):115-46. PubMed ID: 9664203
[TBL] [Abstract][Full Text] [Related]
3. Current management strategies for the prevention and treatment of cytomegalovirus infection in pediatric transplant recipients.
Bueno J; Ramil C; Green M
Paediatr Drugs; 2002; 4(5):279-90. PubMed ID: 11994033
[TBL] [Abstract][Full Text] [Related]
4. New developments in the management of cytomegalovirus infection after solid organ transplantation.
Eid AJ; Razonable RR
Drugs; 2010 May; 70(8):965-81. PubMed ID: 20481654
[TBL] [Abstract][Full Text] [Related]
5. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients.
Hodson EM; Ladhani M; Webster AC; Strippoli GF; Craig JC
Cochrane Database Syst Rev; 2013 Feb; (2):CD003774. PubMed ID: 23450543
[TBL] [Abstract][Full Text] [Related]
6. Similar reduction of cytomegalovirus DNA load by oral valganciclovir and intravenous ganciclovir on pre-emptive therapy after renal and renal-pancreas transplantation.
Kalpoe JS; Schippers EF; Eling Y; Sijpkens YW; de Fijter JW; Kroes AC
Antivir Ther; 2005; 10(1):119-23. PubMed ID: 15751769
[TBL] [Abstract][Full Text] [Related]
7. Cytomegalovirus antigenemia directed pre-emptive prophylaxis with oral versus I.V. ganciclovir for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, controlled trial.
Singh N; Paterson DL; Gayowski T; Wagener MM; Marino IR
Transplantation; 2000 Sep; 70(5):717-22. PubMed ID: 11003347
[TBL] [Abstract][Full Text] [Related]
8. Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients.
Owers DS; Webster AC; Strippoli GF; Kable K; Hodson EM
Cochrane Database Syst Rev; 2013 Feb; 2013(2):CD005133. PubMed ID: 23450558
[TBL] [Abstract][Full Text] [Related]
9. Management of allogeneic bone marrow transplant recipients at risk for cytomegalovirus disease using a surveillance bronchoscopy and prolonged pre-emptive ganciclovir therapy.
Reddy V; Hao Y; Lipton J; Meharchand J; Minden M; Mazzulli T; Chan C; Messner HA
J Clin Virol; 1999 Aug; 13(3):149-59. PubMed ID: 10443791
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of prolonged cytomegalovirus prophylaxis with intravenous ganciclovir in pediatric and young adult lung transplant recipients.
Spivey JF; Singleton D; Sweet S; Storch GA; Hayashi RJ; Huddleston CB; Danziger-Isakov LA
Pediatr Transplant; 2007 May; 11(3):312-8. PubMed ID: 17430489
[TBL] [Abstract][Full Text] [Related]
11. Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients.
Strippoli GF; Hodson EM; Jones CJ; Craig JC
Cochrane Database Syst Rev; 2006 Jan; (1):CD005133. PubMed ID: 16437521
[TBL] [Abstract][Full Text] [Related]
12. Cytomegalovirus prophylaxis and treatment following bone marrow transplantation.
Tsinontides AC; Bechtel TP
Ann Pharmacother; 1996 Nov; 30(11):1277-90. PubMed ID: 8913411
[TBL] [Abstract][Full Text] [Related]
13. Pre-emptive therapy of CMVpp65 antigen positive renal transplant recipients with oral ganciclovir: a randomized, comparative study.
Sagedal S; Nordal KP; Hartmann A; Midtvedt K; Foss A; Asberg A; Degré M; Fauchald P; Rollag H
Nephrol Dial Transplant; 2003 Sep; 18(9):1899-908. PubMed ID: 12937241
[TBL] [Abstract][Full Text] [Related]
14. Dosing of intravenous ganciclovir for the prophylaxis and treatment of cytomegalovirus infection in solid organ transplant recipients.
Fishman JA; Doran MT; Volpicelli SA; Cosimi AB; Flood JG; Rubin RH
Transplantation; 2000 Feb; 69(3):389-94. PubMed ID: 10706048
[TBL] [Abstract][Full Text] [Related]
15. Comparison of intravenous ganciclovir and cytomegalovirus hyperimmune globulin pre-emptive treatment in cytomegalovirus-positive heart transplant recipients.
Vrtovec B; Thomas CD; Radovancevic R; Frazier OH; Radovancevic B
J Heart Lung Transplant; 2004 Apr; 23(4):461-5. PubMed ID: 15063406
[TBL] [Abstract][Full Text] [Related]
16. Cytomegalovirus in transplantation - challenging the status quo.
Fishman JA; Emery V; Freeman R; Pascual M; Rostaing L; Schlitt HJ; Sgarabotto D; Torre-Cisneros J; Uknis ME
Clin Transplant; 2007; 21(2):149-58. PubMed ID: 17425738
[TBL] [Abstract][Full Text] [Related]
17. [Prophylactic and pre-emptive therapy for cytomegalovirus infection in kidney transplant patients using oral valganciclovir].
Guirado L; Rabella N; Díaz JM; Facundo C; Maderuelo A; Margall N; Silva I; García-Maset R; Calabia J; Giménez I; Garra N; Solà R; Ballarín JA
Nefrologia; 2008; 28(3):293-300. PubMed ID: 18590496
[TBL] [Abstract][Full Text] [Related]
18. Formulary considerations for drugs used to prevent cytomegalovirus disease.
Pescovitz MD
Am J Health Syst Pharm; 2003 Dec; 60(23 Suppl 8):S17-21. PubMed ID: 14686231
[TBL] [Abstract][Full Text] [Related]
19. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients.
Hodson EM; Barclay PG; Craig JC; Jones C; Kable K; Strippoli GF; Vimalachandra D; Webster AC
Cochrane Database Syst Rev; 2005 Oct; (4):CD003774. PubMed ID: 16235341
[TBL] [Abstract][Full Text] [Related]
20. Delay of CMV infection in high-risk CMV mismatch lung transplant recipients due to prophylaxis with oral ganciclovir.
Palmer SM; Grinnan DC; Diane Reams B; Steele MP; Messier RH; Duane Davis R
Clin Transplant; 2004 Apr; 18(2):179-85. PubMed ID: 15016133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
